Mobius Therapeutics LLC
This article was originally published in Start Up
Executive Summary
Mobius Therapeutics hopes to make invasive glaucoma surgery, currently a last resort because of complications and high failure rates, safer and more convenient. The company will reformulate mitomycin-c, an anti-fibrotic drug used off-label in glaucoma surgery, pioneer FDA approval for the drug's ophthalmic use, and bring it to market rapidly in an easy-to-use, single-dose kit.